ArticleJAMA oncology2023

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.

William A Hall et al.PubMed ↗Publisher ↗

No numbers read from the abstract.